University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate – AdCOVID – that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.
Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced new results from a preclinical study demonstrating the ability of its AdCOVID vaccine candidate to neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant of concern that originated in South Africa. B.1.351 carries multiple mutations in the receptor binding domain (RBD) including the E484K mutation that has been shown to substantially decrease the ability of authorized vaccines to neutralize the virus.
IMMU 102 – Emerging Coronaviruses. Emerging microbial pathogens are of increasing concern both nationally and internationally with the potential to cause widespread morbidity and mortality at an unprecedented level. The [….]
Altimmune Announces FDA Clearance Of AdCOVID™ IND Application Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week GAITHERSBURG, Md., Feb. [….]